Does active surveillance of serious and life-threatening adverse drug reactions improve reporting? 2011

Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
Patient Safety Section, Therapeutic Effectiveness and Policy Bureau, Marketed Health Products Directorate, Health Canada;

UI MeSH Term Description Entries

Related Publications

Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
September 2010, Pharmacogenomics,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
August 2012, Archives of disease in childhood,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
January 2005, Clinics in dermatology,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
July 2004, Pharmacoepidemiology and drug safety,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
January 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
January 2022, Cancer treatment and research,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
June 1995, American family physician,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
May 1966, JAMA,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
April 2009, Southern medical journal,
Margaret Zimmerman, and Danielle Grenier, and Miriam Levitt
November 1985, Lancet (London, England),
Copied contents to your clipboard!